Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 1.00 |
| ▸ | CES1 | P23141 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.81 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.81 |
| ▸ | MGLL | Q99685 | 1/20 | 0.81 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.81 |
| ▸ | CES2 | O00748 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | TERT | O14746 | 2/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27204763 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL8059738 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL8066150 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL8049506 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL24938531 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL24938529 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL4085373 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL24939095 | 1.00 | FAAH (1.00) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL29038500 | 0.96 | FAAH (0.93) | FAAHCES1MAPTBLMALDH1A1 | |
| SCHEMBL2849161 | 0.96 | FAAH (0.93) | FAAHCES1MAPTBLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240085429-A1 | ALTERING PROTEIN FUNCTION BY PHARMACOLOGICAL TARGETING OF MEMBRANE DOMAINS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | US | disclosed |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3292215-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | The Procter and Gamble Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| WO-2016179561-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-8263558-B2 | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins | ABBOTT LABORATORIES (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090214515-A1 | METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20080213415-A1 | Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations | TAHITIAN NONI INTERNATIONAL, INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1963363-A2 | METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS | Abbott Laboratories (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008098211-A1 | TREATMENT OF GLAUCOMA AND DIABETIC RETINOPATHY WITH MORINDA CITRIFOLIA ENHANCED FORMULATIONS | TAHITIAN NONI INTERNATIONAL, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080167375-A1 | TREATMENT OF CUTANEOUS NEUROGENIC INFLAMMATION | ASTION PHARMA A/S | 2008-07-10 | — | — | US | disclosed |
| WO-2007140791-A1 | TREATMENT OF CUTANEOUS NEUROGENIC INFLAMMATION | ASTION PHARMA A/S (DK) | 2007-12-13 | — | — | WO | disclosed |
| EP-1864657-A1 | Treatment of cutaneous neurogenic inflammation | Astion Pharma A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1572311-A4 | ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070134753-A1 | Assay for determining the activity of fatty acid amide hydrolase | BARBIER ANN J | 2007-06-14 | — | — | US | disclosed |
| WO-2007064917-A2 | METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS | ABBOTT LABORATORIES (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1572311-A2 | ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004037371-A2 | ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167375-A1 | TREATMENT OF CUTANEOUS NEUROGENIC INFLAMMATION | CUTA, SCD, ALOX15B | FAAH 9/4885CES1 657/4885MAPT 734/4885 |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | GSTM2, GSTA2, GSTA1 | FAAH 2168/4885CES1 842/4885MAPT 4761/4885 |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | GSTM2, GSTA2, GSTA1 | FAAH 2168/4885CES1 842/4885MAPT 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.